

Department of Transfusion Medicine Major Publications 2002

Alter HJ. New viruses and their relationship to hepatitis. In: Schinazi RF, Rice C, Sommadosi JP, editors. *Frontiers in Viral Hepatitis*. Netherlands: Elsevier Science, 2002:35-46.

Bolan C, Oral EA, Gorden P, Taylor S, Leitman SF. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. *Journal of Clinical Endocrinology and Metabolism* 2002; 87:380-384.

Bolan CD, Cecco SA, Wesley RA, Horne M, Yau YY, Remaley AT, Childs RW, Barrett AJ, Rehak NN, Leitman SF. Controlled study of citrate effects and response to IV calcium administration during allogeneic peripheral blood progenitor cell donation. *Transfusion* 2002; 42:935-946.

Bolan CD, Yau YY, Carter CS, Cullis H, Leitman S. Effect of device settings and whole blood flow rate (WBFR) on PBSC collection efficiency. *Transfusion* 2002; 42:31S

Bolan CD, Leitman SF. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. *Blood* 2002; 99:1878

Bolan CD, Leitman SF, Griffith LM, Barrett AJ, Childs RW. Parameters of erythropoietic function after major ABO- incompatible hematopoietic stem cell transplantation: implications following nonmyeloablative conditioning - Response. *Blood* 2002; 99:4643-4644.

Browning JN, Sink BS, Leitman S. Simplifying the evaluation of donors who travel to foreign countries. *Transfusion* 2002; 42:118S

Bux J, Stroncek D. Human neutrophil antigens. *Transfusion* 2002; 42:1523

Byrne KM, Stroncek DF, Leitman S. Increasing oxygen tension prevents the occlusion of leukocyte reduction filters by sickle cell trait donor RBCs. *Transfusion* 2002; 42:15S

Candotti F, Podsakoff G, Schurman SH, Muul LM, Engel BC, Carbonaro DA, Jagadeesh GJ, Tuschong LM, Carter CS, RAMSEY WJ, Bauert G, Guo G, Smogorzewska M, Choi C, Hess RA, Hershfield MS, Read EJ, Tisdale JF, Dunbar CE, Kohn DB. Clinical evaluation of retroviral vectors for gene therapy of adenosine deaminase (ADA) deficiency. *Clinical Immunology* 2002; 103:128

Caruccio L, Byrne K, Procter J, Stroncek D. A novel method using formamide for the elution of antibodies from erythrocytes. *Vox Sanguinis* 2002; 83:63-69.

Chambers DR, Procter J, Muratova O, Byrne K, Keister D, Shanks D, Magill A, Stroncek D. In vitro RBC exposure to *Plasmodium falciparum* has no effect on RBC antigen expression. *Transfusion Medicine* 2002; 12:213-219.

Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Kumar S, Goletz TJ, Brown MR, Fleisher TA, Bernstein D, Berzofsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients

with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. *Med Pediatr Oncol* 2002; 38:158-164.

Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. *Medical and Pediatric Oncology* 2002; 38:158-164.

Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. *Journal of Immunotherapy* 2002; 25:243-251.

Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predicts treatment outcome. *Proc Natl Acad Sci U S A* 2002; In press.

Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. *Proceedings of the National Academy of Sciences of the United States of America* 2002; 99:3081-3086.

Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander HR, Libutti SK. Advantages of mRNA amplification for microarray analysis. *Biotechniques* 2002; 33:906-+

Fetsch PA, Simone NL, Bryant-Greenwood PK, Marincola FM, Filie AC, Petricoin EF, Liotta LA, Abati A. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry - Potential for diagnostic applications. *American Journal of Clinical Pathology* 2002; 118:870-876.

Fogarty PF, Huhn RD, Nakamura R, Read EJ, Rick ME, Leitman SF, et al. Intensive immunosuppression with high dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia. *Blood* 2002; In press.

Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, Carter C, Read E, Gea-Banacloche J, Kasten-Sportes C, Kwak L, Wilson W, Levine B, June C, Gress R, Bishop M. Phase I clinical trial of donor T-helper Type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. *Cytotherapy* 2002; 4:429-430.

Greco VA, Byrne KM, Procter JL, Stroncek DF. Detection of antibodies in acid eluates with the gel microcolumn assay. *Transfusion* 2002; 42:698-701.

Greer SE, Leitman S, Shih JW, Conry-Cantilena C, Melpolder JJ, Schechterly C, Nass C, Ness PM, Gibble JW, Alter HJ. A 17-year prospective evaluation of HIV outcomes in a cohort enrolled as asymptomatic blood donors. *Transfusion* 2002; 42:23S

Haddad S, Winer K, Gupta A, Chakrabarti S, Noel P, Klein HG. Munchausen syndrome diagnosed in a puzzling case of anemia. *Transfusion* 2002; 42:43S

Jones TR, Stroncek DF, Gozalo AS, Obaldia N, Andersen EM, Lucas C, Narum DL, Magill AJ, Sim BKL, Hoffman SL. Anemia in parasite- and recombinant protein-immunized Aotus monkeys infected with Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 2002; 66:672-679.

Kang EM, de Witte M, Malech H, Morgan RA, Carter C, Leitman SF, Childs R, Barrett AJ, Little R, Tisdale JF. Gene therapy-based treatment for HIV-positive patients with malignancies. Journal of Hematotherapy & Stem Cell Research 2002; 11:809-816.

Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, Leitman SF, Rodgers GP, Tisdale JF. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99:850-855.

Kang EM, de Witte M, Malech H, Morgan RA, Phang S, Carter C, Leitman SF, Childs R, Barrett AJ, Little R, Tisdale JF. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 2002; 99:698-701.

Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, Leitman SF, Rodgers GP, Tisdale JF. Safety and Feasibility of mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99:855

Klein HG. Blood substitutes: How close to a solution? Oncology-New York 2002; 16:147-151.

Le Poole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM, Kast WM, Robinson JK, Nickoloff BJ. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. American Journal of Pathology 2002; 160:521-528.

Leiby DA, Herron RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: Impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002; In press.

Leitman S, Oblitas J, Sparks E, Browning JN. Commitment to blood donation by disaster appeal respondents. Transfusion 2002; 42:123S-124S.

Lockwood FL, Csako G, Choyke P, Cannon R, Wesley R, Ruiz M, Giesel F, Fu X, Costello R, Leser M, Schenke W, Sink B, Pucino F, Leitman S. Frequent blood donation fails to improve markers of atherosclerosis. Transfusion 2002; 42:65S-66S.

Monsurro V, Rosenberg S, Marincola F. Functional heterogeneity of vaccine-induced CD8+T cell subsets. Clinical Immunology 2002; 103:296

Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM. Functional heterogeneity of vaccine-induced CD8(+) T cells. Journal of Immunology 2002; 168:5933-5942.

Nagorsen D, Monsurro V, Wang E, Marincola FM. Characterization of CD8(-) HLA class I epitope tetrameric complexes binding T cells. *Journal of Immunotherapy* 2002; 25:379-384.

Panelli MC, Wang E, Monsurro V, Marincola FM. The role of quantitative PCR for the immune monitoring of cancer patients. *Expert Opinion on Biological Therapy* 2002; In press.

Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A. Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going? *Journal of the National Cancer Institute* 2002; 94:805-818.

Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM. Intensity of the vaccine-elicited immune response determines tumor clearance. *Journal of Immunology* 2002; 168:338-347.

Provenzano M, Mocellin S, Bettinotti M, Preuss J, Monsurro V, Marincola FM, Stroncek D. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. *Journal of Immunotherapy* 2002; 25:342-351.

Rabkin CS, Tess BH, Christianson RE, Wright WE, Waters DJ, Alter HJ, et al. Prospective study of hepatitis C virus infection as a risk factor for subsequent B cell neoplasia. *Blood* 2002; In press.

Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM. Frequency of MART-1/MelanA and gp100/PMel117-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. *Journal of Immunotherapy* 2002; 25:252-263.

Solomon SR, Tran T, Carter C, Donnelly S, Hensel N, Schindler J, Bahcecí E, Ghetie V, Michalek J, Mavroudis D, Read EJ, Vitetta E, Barrett AJ. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. *Cytotherapy* 2002; 4:395-406.

Stroncek D, Bux J. Is it time to standardize granulocyte alloantigen nomenclature? *Transfusion* 2002; 42:393-395.

Stroncek D. Neutrophil-specific antigen HNA-2a (NB1, CD177): Serology, biochemistry, and molecular biology. *Vox Sanguinis* 2002; 83:359-361.

Stroncek D. Neutrophil alloantigens. *Transfusion Medicine Reviews* 2002; 16:67-75.

Stroncek DF, Matthews CL, Follmann D, Leitman SF. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. *Transfusion* 2002; 42:597-602.

Stroncek DF, Rainer T, Sharon V, Byrne KM, Noguchi CT, Klein HG, Schechter AN, Leitman SF. Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. *Transfusion* 2002; 42:1466-1472.

Tanaka Y, Hanada K, Mizokami M, Yeo AET, Shih JWK, Gojobori T, Alter HJ. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. *Proceedings of the National Academy of Sciences of the United States of America* 2002; 99:15584-15589.

Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzenbuber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma. *Journal of Clinical Oncology* 2002; 20:142-152.

Umemura T, Tanaka Y, Kiyosawa K, Alter HJ, Shih JWK. Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus). *Febs Letters* 2002; 510:171-174.

Umemura T, Alter HJ, Tanaka E, Orii K, Yeo AET, Shih JWK, Matsumoto A, Yoshizawa K, Kiyosawa K. SEN virus: Response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. *Hepatology* 2002; 35:953-959.

Umemura T, Yeo AET, Wang RYH, Shih JWK, Alter HJ. The role of SEN virus infection in various liver diseases from different geographic regions. *Hepatology* 2002; In press.

Umemura T, Primi D, Alter HJ. Transfusion associated SEN virus infection and its relationship to liver disease. In: Margolis M, Alter HJ, Liang TJ, editors. *Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease*. London: International Medical Press, 2002:

Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diaz A, Petersen D, Zhao YD, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. *Cancer Research* 2002; 62:3581-3586.

Wang HY, Zhou YH, Zhu KC, Riker AI, Marincola FM, Wang RF. Identification of a mutated fibronectin as a tumor antigen recognized by CD4(+) T cells: Its role in extracellular matrix formation and tumor metastasis. *Journal of Experimental Medicine* 2002; 195:1397-1406.

Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. Impaired effector function of hepatitis C virus-specific CD8(+) T cells in chronic hepatitis C virus infection. *Journal of Immunology* 2002; 169:3447-3458.

Wong ECC, Lee SM, Hines K, Lee J, Carter CS, Kopp W, Bender J, Read EJ. Development of a closed system process for clinical-scale generation of dendritic cells: Evaluation of two monocyte enrichment methods and two culture containers. *Cytotherapy* 2002; 4:65-76.